Condition

EGFR Exon 19 Deletion

ClinicalTrials.gov condition label

Clinical trials4

Recruiting0

Common interventions8

Lead sponsors shown3

Clinical trials

4 shown

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)NCT05998993 · 2023-11-01

NOT_YET_RECRUITING

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyNCT05338970 · 2022-07-08

ACTIVE_NOT_RECRUITING

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCNCT05153408 · 2022-01-13

TERMINATED

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780 · 2021-06-29

TERMINATED

Common interventions

osimertinibDRUG2BLU-701DRUG1BLU-945DRUG1carboplatinDRUG1Patritumab DeruxtecanDRUG1pemetrexedDRUG1Platinum-based chemotherapyDRUG1Stereotactic Body Radiation Therapy SBRTRADIATION1

Leading sponsors

Blueprint Medicines Corporation2Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo1Daiichi Sankyo1

Trial status mix

TERMINATED2

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

Phase mix

PHASE12

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.